Demographic profile (n)

No dysfunction (n = 82)

Dysfunction (n = 28)

p-value

Crude odd ratio (CI)

Adjusted OR (CI)

Age

<5 yrs (46)

>5yrs (64)

37 (45%)

45 (55%)

9 (32%)

19 (68%)

0.276

1.736 (0.703 - 4.289)

Sex

Males (75)

Females (35)

54 (66%)

28 (34%)

21(75%)

7 (25%)

0.487

1.556 (0.590 - 4.102)

Type of malignancy

Hematological (94)

Solid tumors (16)

71 (87%)

11 (13%)

23 (82%)

5 (18%)

0.756

1.403 (0.441 - 4.463)

Daunorubicin

Daunorubicin + Doxorubicin

6 (7%)

76 (93%)

10 (36%)

18 (64%)

0.001

7.037 (2.262 - 21.895)

-

^*Mode of delivery

Bolus (106)

Infusion (4)

81 (99%)

1(1%)

25(89%)

3 (11%)

0.048

9.72 (0.968 - 97.647)

-

Cumulative anthracycline dose

<300 mg (95)

>300 mg (15)

78 (95%)

4 (5%)

17 (61%)

11 (39%)

<0.001

12.618 (3.583 - 44.43)

2.25 (0.032 - 0.522)

Radiation therapy (24)

13 (16%)

11 (39%)

0.009

3.434 (1.312 - 8.992)

3.46 (0.115 - 0.427)

^*Down’s syndrome (8)

5 (6%)

3 (11%)

0.331

1.848 (0.412 - 8.288)

Sepsis (47)

28 (34%)

19 (68%)

0.002

4.071 (1.631 - 10.166)

2.58 (0.040 - 0.305)